August 05, 2024
Chinese Drug Co. Says Sanctions In Valsartan MDL Too Harsh

Chinese drug firm Zhejiang Huahai Pharmaceutical Co. Ltd. told a New Jersey federal court Friday that sanctions authorizing two adverse jury instructions in multidistrict litigation over generic drugs contaminated with carcinogens should be overturned, arguing the plaintiffs did not allege the bad faith required for such a harsh penalty.

15 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

Direct access to case information and documents.
All significant new filings across U.S. federal district courts, updated hourly on business days.
Full-text searches on all patent complaints in federal courts.
No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login

VALSARTAN LOSARTAN AND IRBESARTAN PRODUCTS LIABILITY LITIGATION

Case Number:

Court:

Nature of Suit:

Multi Party Litigation:

Judge:

Firms

Companies

Sectors & Industries:

View recent docket activity

Coverage

Chinese Drug Co. Says Sanctions In Valsartan MDL Too Harsh

Parties

Stay ahead of the curve